CureVac Review, Focusing on 2nd-Gen COVID Vaccine
<p>Analysts at Berenberg Bank provided their outlook on <a href='https://financialmodelingprep.com/financial-summary/CVAC'>CureVac N.V. (NASDAQ:CVAC)</a>, mentioning that they believe the withdrawal of first-generation CVnCoV from the approval process effectively removes an overhang from the stock. </p>
<p>According to the analysts, they like the potential of the GlaxoSmithKline (GSK) partnered second-generation COVID-19 vaccine (CV2CoV) and believe it has the potential to capture what they expect will be an active booster market given the virus likely continues to mutate; the emergence of the omicron variant being a prime example of this. </p>

NASDAQ:CVAC